COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - share repurchase programme

16/09/2024 - 15:15

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]

Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy

16/09/2024 - 15:00

Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therapy Equillium targeting initiation of Phase 1 study investigating EQ302 in 2H 2025 [...]

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

16/09/2024 - 15:00

GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]

London Man Grateful to Doctors Who Treated Rare Flesh-Eating Disease, Pledges $25,000

16/09/2024 - 15:00

LONDON, Ontario, Sept. 16, 2024 (GLOBE NEWSWIRE) -- While on vacation in Napa Valley last year, Colleen DeJager’s world imploded when she received a startling call from back home—her husband Rick was admitted to London [...]

T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

16/09/2024 - 15:00

Expands available market to include over 200 children’s hospitals in the United States LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid [...]

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

16/09/2024 - 14:53

Strengthens Rare Disease segment as largest driver of future growth , adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth [...]

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

16/09/2024 - 14:45

Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx ® (cabozantinib) versus placebo in advanced pancreatic and extra-pancreatic [...]

Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées

16/09/2024 - 14:45

Les données ont démontré une réduction significative, tant sur le plan statistique que sur le plan clinique, du risque de progression de la maladie ou de décès avec Cabometyx ® (cabozantinib) par rapport au placebo dans [...]

NeuroStar® Releases Software Upgrades to Elevate Patient Care

16/09/2024 - 14:32

Upgrades improve communication, streamline data management, and strengthen security MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, [...]

Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients

16/09/2024 - 14:30

In the US pivotal trial, WRAPSODY achieved 89.8% target lesion primary patency at 6 months SOUTH JORDAN, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare [...]

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

16/09/2024 - 14:30

SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical [...]

BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research

16/09/2024 - 14:30

Partnership increases physician and patient participation in clinical trials GRAND RAPIDS, Mich. and SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BAMF Health, a world leader in molecular imaging and Theranostics [...]

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

16/09/2024 - 14:30

Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for [...]

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

16/09/2024 - 14:30

September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant Funds to Advance Development of Phase 3 Asset Biodexa Pharmaceuticals [...]

Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies

16/09/2024 - 14:30

Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

15/09/2024 - 15:45

Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1 Injected and non- [...]

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

15/09/2024 - 14:45

Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses [...]

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

15/09/2024 - 14:45

Trial investigating Cabometyx ® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet statistical [...]

Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale

15/09/2024 - 14:45

L’essai portant sur Cabometyx ® (cabozantinib) en association avec l’atézolizumab a démontré une tendance positive à l’amélioration de l’un des critères d’évaluation principaux de la survie globale, sans atteindre la [...]